Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Keir, M. Butte, G. Freeman, A. Sharpe (2008)
PD-1 and its ligands in tolerance and immunity.Annual review of immunology, 26
D. Keizman, M. Ish‐shalom, Peng Huang, M. Eisenberger, R. Pili, H. Hammers, M. Carducci (2012)
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.European journal of cancer, 48 2
(2016)
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancerOncotarget, 7
A. Giacomo, L. Calabrò, R. Danielli, E. Fonsatti, E. Bertocci, I. Pesce, C. Fazio, Ornella Cutaia, D. Giannarelli, C. Miracco, M. Biagioli, M. Altomonte, M. Maio (2013)
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programmeCancer Immunology, Immunotherapy, 62
R. Herbst, P. Baas, Dong-Wan Kim, E. Felip, J. Pérez-Gracia, Ji-Youn Han, J. Molina, Joo‐Hang Kim, C. Arvis, M. Ahn, M. Majem, M. Fidler, G. Castro, M. Garrido, G. Lubiniecki, Shentu Yue, E. Im, M. Dolled-Filhart, E. Garon (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 387
Yuecan Zeng, F. Chi, R. Xing, M. Xue, Li-na Wu, M. Tang, R. Wu (2015)
Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.Japanese journal of clinical oncology, 46 2
Q. Qin, Baosheng Li (2019)
Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directionsJournal of Cancer Research and Therapeutics, 15
T. Eigentler, J. Hassel, C. Berking, J. Aberle, O. Bachmann, V. Grünwald, K. Kähler, C. Loquai, N. Reinmuth, M. Steins, L. Zimmer, A. Sendl, R. Gutzmer (2016)
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.Cancer treatment reviews, 45
E. Simeone, G. Gentilcore, D. Giannarelli, A. Grimaldi, C. Caracò, M. Curvietto, Assunta Esposito, Miriam Paone, M. Palla, E. Cavalcanti, F. Sandomenico, A. Petrillo, G. Botti, F. Fulciniti, G. Palmieri, P. Queirolo, P. Marchetti, V. Ferraresi, G. Rinaldi, M. Pistillo, G. Ciliberto, N. Mozzillo, P. Ascierto (2014)
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanomaCancer Immunology, Immunotherapy, 63
Youngjoo Lee, Sun Kim, Ji-Youn Han, Heung Kim, T. Yun, J. Lee (2012)
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapyJournal of Cancer Research and Clinical Oncology, 138
P. Ferrucci, S. Gandini, A. Battaglia, S. Alfieri, A. Giacomo, D. Giannarelli, G. Cappellini, F. Galitiis, P. Marchetti, G. Amato, Andrea Lazzeri, L. Pala, E. Cocorocchio, C. Martinoli (2015)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patientsBritish Journal of Cancer, 112
E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M. Ahn, E. Felip, Jong-Seok Lee, M. Hellmann, O. Hamid, J. Goldman, J. Soria, M. Dolled-Filhart, R. Rutledge, Jin Zhang, J. Lunceford, Reshma Rangwala, G. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi (2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.The New England journal of medicine, 372 21
S. Bagley, S. Kothari, C. Aggarwal, J. Bauml, E. Alley, T. Evans, J. Kosteva, C. Ciunci, P. Gabriel, Jeffrey Thompson, Susan Stonehouse-Lee, V. Sherry, Elizabeth Gilbert, B. Eaby-Sandy, F. Mutale, G. Dilullo, R. Cohen, A. Vachani, C. Langer (2017)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.Lung cancer, 106
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
S. Patel, R. Kurzrock (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 14
Q. You, Linling Cheng, R. Kedl, C. Ju (2008)
Mechanism of T cell tolerance induction by murine hepatic Kupffer cellsHepatology, 48
T. Sejima, H. Iwamoto, Shuichi Morizane, N. Hinata, Akihisa Yao, T. Isoyama, M. Saito, A. Takenaka (2013)
The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.Urologic oncology, 31 7
I. Crispe (2009)
The liver as a lymphoid organ.Annual review of immunology, 27
Bo Hu, Xinrong Yang, Yang Xu, Yunfan Sun, Chao Sun, W. Guo, Xin Zhang, Wei-min Wang, S. Qiu, Jian Zhou, Jia Fan (2014)
Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular CarcinomaClinical Cancer Research, 20
A. Templeton, M. McNamara, B. Seruga, F. Vera-Badillo, P. Aneja, A. Ocaña, R. Leibowitz-Amit, G. Sonpavde, J. Knox, B. Tran, I. Tannock, E. Amir (2014)
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.Journal of the National Cancer Institute, 106 6
J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel, L. Zitvogel, N. Chaput, Séverine Roy, A. Eggermont, É. Routier, C. Robert (2013)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.Annals of oncology : official journal of the European Society for Medical Oncology, 24 6
R. Kumar, E. Geuna, V. Michalarea, M. Guardascione, Ulrike Naumann, D. Lorente, S. Kaye, J. Bono (2015)
The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trialsBritish Journal of Cancer, 112
Zongguo Yang, Jianliang Zhang, Yunfei Lu, Qingnian Xu, Bozong Tang, Qiang Wang, Wensi Zhang, Shishi Chen, Lingqing Lu, Xiaorong Chen (2015)
Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolizationOncotarget, 6
C. Wahl, Petra Bochtler, Lieping Chen, R. Schirmbeck, J. Reimann (2008)
B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses.Gastroenterology, 135 3
W. Chua, K. Charles, V. Baracos, Stephen Clarke (2011)
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancerBritish Journal of Cancer, 104
Hendrik Ungefroren, S. Sebens, Daniel Seidl, Hendrik Lehnert, Ralf Hass (2011)
Interaction of tumor cells with the microenvironmentCell Communication and Signaling : CCS, 9
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, F. Finckenstein, J. Brahmer (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 17
C. Jenne, P. Kubes (2013)
Immune surveillance by the liverNature Immunology, 14
K. Suh, Se Kim, Y. Kim, Miso Kim, B. Keam, T. Kim, Dong-Wan Kim, D. Heo, J. Lee (2017)
P3.02c-061 Neutrophil/Lymphocyte Ratio Predicts the Efficacy of Anti-PD-1 Antibody in Patients with Advanced Lung Cancer: Topic: IT BiomarkersJournal of Thoracic Oncology, 12
K. Shien, V. Papadimitrakopoulou, I. Wistuba (2016)
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.Lung cancer, 99
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 2
A. Templeton, J. Knox, Xun Lin, R. Simantov, W. Xie, N. Lawrence, R. Broom, A. Fay, B. Rini, F. Donskov, G. Bjarnason, M. Smoragiewicz, C. Kollmannsberger, R. Kanesvaran, N. Alimohamed, T. Hermanns, J. Wells, E. Amir, T. Choueiri, D. Heng (2016)
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.European urology, 70 2
G. Guthrie, K. Charles, C. Roxburgh, P. Horgan, D. McMillan, S. Clarke (2013)
The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.Critical reviews in oncology/hematology, 88 1
Michael Bomble, F. Tacke, L. Rink, E. Kovalenko, R. Weiskirchen (2010)
Analysis of antigen-presenting functionality of cultured rat hepatic stellate cells and transdifferentiated myofibroblasts.Biochemical and biophysical research communications, 396 2
KJ Suh, SH Kim, YJ Kim (2017)
P3.02c-061 Neutrophil/lymphocyte ratio predicts the efficacy of anti-PD-1 antibody in patients with advanced lung cancerJ Thorac Oncol, 12
C. O’Gorman, A. Macken, W. Cullen, J. Saunders, C. Dunne, M. Higgins (2013)
What is a randomised controlled trial?Irish medical journal, 106 2 Suppl
Guohe Lin, Yongcheng Liu, Shu-hong Li, Y. Mao, Jun Wang, Zeyu Shuang, Jianlin Chen, Sheng-ping Li (2016)
Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinomaOncotarget, 7
D. Hanahan, R. Weinberg (2011)
Hallmarks of Cancer: The Next GenerationCell, 144
We investigated inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) that may predict the response to anti-PD-1 (programmed cell death protein 1) antibody therapy. Data from 54 patients with non-small cell lung cancer (NSCLC) treated with anti-PD-1 antibodies were retrospectively analyzed. The NLR was assessed at baseline and 6 weeks after the start of treatment (post-treatment). Eighteen of 54 patients (33.3%) had objective responses to treatment. Older age, absence of brain metastasis, low post-treatment NLR (< 5), and immune-related adverse events were significantly associated with response. Patients with a high post-treatment NLR (≥ 5) had significantly shorter progression-free survival (PFS) than those with a low post-treatment NLR (median, 1.3 vs. 6.1 months, p < 0.001). Multivariate analysis demonstrated that high post-treatment NLR [hazard ratio (HR) 15.1, 95% confidence interval (CI) 1.5–50.1, p < 0.001], liver metastasis (HR 4.9, 95% CI 1.9–12.4, p = 0.001), and brain metastasis (HR 3.2, 95% CI 1.3–8.2, p = 0.013) were independent prognostic factors of shorter PFS. Overall survival (OS) was significantly different in patients with high and low post-treatment NLRs (median, 2.1 vs. 14.0 months, p < 0.001). A high post-treatment NLR remained an independent prognostic factor for OS in multivariate analysis (HR 3.9, 95% CI 1.6–9.2, p = 0.003). The NLR at 6 weeks after treatment initiation was a prognostic marker in patients with advanced NSCLC treated with anti-PD-1 antibody. Further studies are warranted to evaluate the role of the 6-week NLR as a predictor in anti-PD-1 antibody treatment.
Cancer Immunology, Immunotherapy – Springer Journals
Published: Dec 4, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.